Wednesday, Adial Pharmaceuticals Inc ADIL announced the publication of a peer-reviewed article highlighting the clinical results, strong safety profile, and high compliance among patients administered AD04 (low-dose ondansetron).
AD04 is the company’s lead investigational new drug product being developed for the treatment of Alcohol Use Disorder (AUD).
The publication also reported the results of a new study analyzing the liver safety profile of AD04 compared with placebo in subjects with AUD in the company’s prior Phase 3 trial.
The published study provides a comprehensive analysis of the liver safety profile of AD04 compared to a placebo in individuals with AUD and a specific 5-marker genetic profile.
AUD, characterized by compulsive alcohol consumption and loss of control over intake, poses significant health risks and is a major contributor to alcohol-associated liver disease.
According to the publication, low-dose AD04 did not significantly change biochemical markers of liver injury, such as ALT, AST, and Serum Bilirubin.
Additionally, while patients with AUD displayed elevated liver enzyme gamma-glutamyl transferase, typically associated with increased alcohol consumption, this parameter remained unaffected by low-dose AD04.
Additionally, no significant adverse effects were observed due to oral low-dose AD04 treatment.
The publication also highlighted that low-dose AD04 demonstrated an improved safety and tolerability profile compared to placebo, featuring a low occurrence of adverse events (AEs), high medication compliance, and a minimal dropout rate.
In February, Adial Pharmaceuticals received a U.S. patent covering AD04 and its ability to target the serotonin transporter gene for the potential treatment of opioid use disorder.
The company says the new patent strengthens Adial’s patent portfolio and covers AD04’s ability to target the serotonin transporter gene for the potential treatment of opioid use disorder.
Price Action: ADIL shares closed at $1.13 on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
